Page last updated: 2024-12-07

androsta-1,4,6-triene-3,17-dione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

androsta-1,4,6-triene-3,17-dione: blocks aromatization of testosterone to estradiol; aromatase antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

androsta-1,4,6-triene-3,17-dione : An androstanoid that is androsta-1,4,6-triene substituted by oxo groups at positions 3 and 17. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID104880
CHEMBL ID2311178
CHEBI ID131190
SCHEMBL ID132874
MeSH IDM0058139

Synonyms (20)

Synonym
androsta-1,4,6-triene-3,17-dione
a146-t317d
1,4,6-androstatriene-3,17-dione
1,4,6-andorstatriene-3,17-dione
ATD ,
1,4,6-etioallochan-dione
CHEBI:131190
633-35-2
(8r,9s,10r,13s,14s)-10,13-dimethyl-9,11,12,14,15,16-hexahydro-8h-cyclopenta[a]phenanthrene-3,17-dione
217a6t1v8n ,
unii-217a6t1v8n
1,4,6 etioallocholan-dione
CHEMBL2311178 ,
bdbm50421878
SCHEMBL132874
AKOS030240786
DTXSID60862328
Q4545687
HY-136092
CS-0119570

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" However, they were no less receptive than control females in response to a high (15 micrograms/kg) dosage of EB."( Effect of prenatal exposure to aromatase inhibitor, testosterone, or antiandrogen on the development of feminine sexual behavior in ferrets of both sexes.
Baum, MJ; Tobet, SA, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 1.14.14.14 (aromatase) inhibitorAn EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor which interferes with the action of aromatase (EC 1.14.14.14) and so reduces production of estrogenic steroid hormones.
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
17-oxo steroidAny oxo steroid carrying the oxo group at position 17.
androstanoidAny steroid based on an androstane skeleton and its derivatives.
3-oxo-Delta(1),Delta(4)-steroidA 3-oxo-Delta(1) steroid containing an additional double bond between positions 4 and 5.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AromataseHomo sapiens (human)Ki0.09130.00000.60469.5010AID1270809; AID53739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID53739Binding affinity was measured on Cytochrome P450 19A11990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Mechanism and inhibition of cytochrome P-450 aromatase.
AID54197Percent inhibition of human placental Cytochrome P450 19A1 at 3:1 inhibitor: androstenedione (0.7 uM) ratio1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives.
AID53725Percent inhibition of human placental Cytochrome P450 19A1 at 3:1 inhibitor: androstenedione (0.7 uM) ratio1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives.
AID1270809Competitive inhibition of human aromatase extracted from placental microsomes after 5 mins by Dixon plot analysis in presence of [1beta-3H]AD2015European journal of medicinal chemistry, Nov-13, Volume: 105Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
AID23785Half life period was determined1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Mechanism and inhibition of cytochrome P-450 aromatase.
AID53717Percent inhibition of human placental Cytochrome P450 19A1 at 1:1 inhibitor: androstenedione (0.7 uM) ratio1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives.
AID54196Percent inhibition of human placental Cytochrome P450 19A1 at 1:1 inhibitor: androstenedione (0.7 uM) ratio1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (110)

TimeframeStudies, This Drug (%)All Drugs %
pre-199062 (56.36)18.7374
1990's24 (21.82)18.2507
2000's12 (10.91)29.6817
2010's11 (10.00)24.3611
2020's1 (0.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (3.54%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other109 (96.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]